Form 4 for RNAC Cartesian Therapeutics, Inc.
Accepted 2024-12-30 00:00:00 ET · period of report 2024-12-26 · accession 0001453687-24-000149 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-12-30 | 2024-12-26 | RNAC | English Emily | SVP, Head of Manufacturing | M - OptEx | $3.30 | +7,650 | 25.9K | +42% | +$25.2K |
| D | 2024-12-30 | 2024-12-26 | RNAC | English Emily | SVP, Head of Manufacturing | M - OptEx | — | -7,650 | 49.4K | -13% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-26 | M | A | 7,650 | $3.30 | 25,923 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2024-12-26 | M | D | 7,650 | — | 49,369 | D | $3.30 · — to 2031-04-25 | 7,650 Common Stock | (F2) On November 13, 2023, the issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of Common Stock in connection with the merger. (F1) These options are currently exercisable for an additional 35,114 shares of Common Stock and become exercisable for a further 14,255 shares of Common Stock on March 22, 2025. |